Monday, June 1, 2026
← Back to archivePolicy
Policy•STAT News•Jun 1, 2026
The hidden history of BPC-157, a favorite MAHA peptide
background ▾
- •BPC-157 remains a gray-market compound without FDA approval despite 50+ years of research and claimed broad therapeutic effects, indicating a significant gap between academic promotion and regulatory acceptance.
- •The peptide's association with MAHA's drug regulation reform agenda suggests potential political pressure to expedite approval or change classification pathways for compounds lacking robust clinical trial data.
- •The investigative framing (including the term 'bootleg panacea') signals media skepticism about scientific claims and regulatory gaps that warrant close monitoring as BPC-157 gains consumer visibility.
BPC-157
→ Read original articlePolicy•STAT News•Jun 1, 2026
Opinion: Medical schools diversified. So where are all the diverse doctors?
background ▾
- •Black resident physicians are dismissed at four times the rate of their representation in residency populations (20% of dismissals vs. 5% of residents), suggesting systemic bias in training program gatekeeping.
- •Residency disciplinary processes lack standardization, transparency, and due process, with subjective 'professionalism' assessments creating space for implicit bias to influence career-ending decisions.
- •Watch for potential regulatory or legislative responses requiring residency programs to report demographic data on completion, remediation, and dismissal rates, similar to existing diversity reporting mandates.
Policy•STAT News•Jun 1, 2026
Opinion: The military’s medical corps has a serious recruitment problem
background ▾
- •Military physicians earn substantially below civilian compensation across two-thirds of specialties, with procedural specialists facing gaps exceeding $400,000 annually, making recruitment and retention increasingly untenable.
- •A June 2025 DoD Inspector General report documented that emergency medical officers are being assigned to non-clinical roles, degrading their clinical skills below wartime readiness standards—a systemic readiness risk.
- •Monitor whether the DoD announces compensation restructuring, recruitment incentives, or policy reforms in response to this documented crisis, as the convergence of military readiness needs and civilian talent shortage creates urgency for institutional change.
Policy•KFF•May 29, 2026
A Closer Look at North Carolina’s Implementation of the 2025 Reconciliation Law Medicaid Provisions and Other Changes Amid Medicaid Budget Shortfalls
background ▾
- •The 2025 reconciliation law mandates work requirements for ACA Medicaid expansion enrollees starting January 1, 2027, with North Carolina implementing stricter standards than federally required, signaling potential for significant coverage losses.
- •North Carolina's temporary elimination of GLP-1 coverage due to budget shortfalls demonstrates how state Medicaid fiscal crises can immediately affect pharmaceutical access and highlights vulnerability of newer drug coverage amid cost pressures.
- •Monitor how other states implement reconciliation law work requirements and state-directed payment restrictions over 2026-2027, as North Carolina's approach may influence national patterns in coverage restrictions and provider reimbursement constraints.
GLP-1
→ Read original articlePolicy•Fierce Biotech•May 29, 2026
Boston, China and the future of biotech
background ▾
- •Boston biotech leaders acknowledge growing global competition and pressure to innovate faster, with particular attention to China's rapid innovation model and alternative operating approaches
Flagship PioneeringPassKeyMassBio
→ Read original articleMarket Access
Market Access•Fierce Pharma•Jun 1, 2026
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
background ▾
- •Pfizer's $10B Innovent deal signals confidence in Chinese oncology assets despite mounting U.S. hawkishness on China biotech partnerships
- •Geopolitical tensions may constrain future similar deals or require heightened regulatory/political scrutiny of China biotech collaborations
- •Monitor U.S. regulatory and legislative actions targeting foreign biotech partnerships, and Astellas' ability to execute its patent cliff mitigation strategy
PfizerInnovent BiologicsAstellas Pharma
→ Read original articleMarket Access•Fierce Biotech•Jun 1, 2026
Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
background ▾
- •Lilly's $1.2B deal for sonefpeglutide represents a commercial bet on long-acting GLP-2 dosing convenience in an unmet SBS market dominated by one approved agent (Gattex), with potential to capture market share if monthly subcutaneous administration proves non-inferior to daily injections.
- •Hanmi's long-acting peptide platform (Lapscovery) has already generated regulatory success (Rolvedon approval 2022), validating the underlying technology and reducing clinical risk for sonefpeglutide, though phase 2 efficacy and safety data in SBS patients remain the critical path to value realization.
- •Watch for phase 2 trial completion and Lilly-sponsored phase 3 initiation timeline; any safety signals or efficacy gaps versus Gattex will determine commercial viability; competitive pressure may intensify if other GLP-2 programs advance or if GLP-1/GLP-2 combination approaches emerge in GI indications.
Eli LillyHanmi PharmaceuticalsTakedasonefpeglutideGattexglepaglutide
→ Read original articleMarket Access•Fierce Pharma•Jun 1, 2026
MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
background ▾
- •Afrezza pediatric approval represents the first major label expansion for this product in over a decade, directly addressing a significant unmet need in pediatric diabetes management.
- •MannKind's commercial trajectory has been challenged by limited adoption despite first-mover advantage in inhaled insulin; pediatric indication could improve payer negotiations and formulary positioning.
- •Monitor for payer coverage decisions, pediatric prescriber adoption rates, and whether this approval catalyzes broader market acceptance or faces similar adoption barriers as the adult indication.
MannKindAfrezza
→ Read original articleMarket Access•Endpoints News•May 29, 2026
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
background ▾
- •AstraZeneca is pursuing alternative development strategies for anselamimab following Phase 3 failure, suggesting potential pivot to different indication or patient subset rather than full program termination
- •Imfinzi and Tremfya label expansions expand addressable markets for established revenue generators
- •Monitor anselamimab's next indication and trial design; track Imfinzi and Tremfya uptake in expanded indications
AstraZenecaanselamimabImfinzidurvalumab
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•Jun 1, 2026
ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
background ▾
- •Monjuvi combination showed positive phase 3 results across DLBCL patient subgroups, supporting first-line positioning against R-CHOP and Polivy
- •Incyte faces intensifying competition from bispecific antibodies and T-cell engagers that could limit Monjuvi's market window
- •Watch for regulatory filings, payer coverage decisions, and whether clinical data supports meaningful superiority over standard-of-care regimens
IncyteRocheMonjuviPolivyR-CHOP
→ Read original articleClinical Trials•Fierce Biotech•May 31, 2026
ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
background ▾
- •KLN-1010 achieved 100% MRD negativity in 18 heavily pretreated myeloma patients with no preconditioning requirement and an exceptionally clean safety profile (no infusion reactions), validating Lilly's strategic bet on in vivo CAR-T as a scalable platform.
- •Lilly intends to skip traditional Phase 2 and move directly to a suite of randomized Phase 3 trials, accelerating development but introducing regulatory risk if Phase 1 data do not hold in larger, more diverse populations.
- •Watch for Phase 3 trial initiation, dose optimization decisions, and expansion into lymphoma and solid tumors; monitor for any safety signals or durability concerns as follow-up extends beyond 10 months and patient cohorts enlarge across U.S. sites.
Eli LillyKelonia TherapeuticsKLN-1010
→ Read original articleClinical Trials•Fierce Biotech•May 30, 2026
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
background ▾
- •TUB-040 achieved 61% response rate in heavily pretreated platinum-resistant ovarian cancer patients (median 4 prior therapies) with 11-month PFS, substantially exceeding the 5-month standard of care benchmark
- •Gilead is advancing phase 3 discussions with FDA and developing earlier-line combination strategies, signaling confidence in the program's expansion potential
- •The acquisition rationale extends beyond TUB-040 to Tubulis's ADC platform technology, which Gilead plans to establish as a dedicated innovation center in Munich with potential applications in inflammation and virology
Gilead SciencesTubulisGenentechTUB-040Avastin
→ Read original articleClinical Trials•Fierce Biotech•May 29, 2026
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
background ▾
- •Tebapivat missed its primary transfusion endpoint in LR-MDS despite prior phase 2a data suggesting meaningful clinical benefit, indicating patient stratification challenges in this indication
- •Agios is discontinuing LR-MDS development but banking on the sickle cell disease phase 2 program, with critical readout expected by end of H2 2024
- •The failure underscores execution risks in the PK activator class; Pyrukynd itself showed mixed phase 3 results in SCD last year, making tebapivat's upcoming SCD data a pivotal moment for program viability
Agios PharmaceuticalstebapivatPyrukyndAqvesme
→ Read original articleClinical Trials•Fierce Biotech•May 31, 2026
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
background ▾
- •Ivonescimab plus chemotherapy achieved 34% OS improvement over PD-1 inhibitor plus chemo in squamous NSCLC (p=0.0017), meeting prespecified significance boundary and exceeding the typical 30% threshold considered a major win
- •Benefit was consistent across PD-L1-negative (36%) and PD-L1-positive (32%) patients, and expert review by independent oncologists confirmed the comparator arm performance was not substandard, validating the survival signal
- •Watch for: regulatory submissions outside China, potential label expansion in non-squamous NSCLC, comparative efficacy data versus other bispecifics, and impact on Akeso's valuation and competitive positioning in oncology
AkesoMerck & Co.BeOne MedicinesivonescimabKeytrudaTevimbra
→ Read original article